Bio Insight Bio Analysis
Drug discovery is an expensive, slow, and risky endeavor, with many clinical trials failing at the final hurdle. Maintaining R&D productivity at a sust...
July 06, 2021 | Opinion
Risk & Reward Index Industry Rewards 44.4 Industry Risk 80.9 Regional Rank 08 ...
June 17, 2021 | Analysis
As part of this process, we interviewed nine persons external to CDC from diverse backgrounds and organizations that represent the leading edge of human ge...
June 17, 2021 | Analysis | By Katherine Kolor, Ridgely Fisk Green, and Muin J. Khoury, Office of Genomics and Precision Public Health, Centers for Disease Control and Prevention, Atlanta, Georgia
The launch of innovative drugs will drive growth in the market. Hong Kong is the leading choice for manufacturers of home-based equipment, hygiene-steriliz...
June 15, 2021 | News
Frost & Sullivan's recent analysis, Impact of COVID-19 on Elective Procedures in Western Europe, 2020–2023, finds that the Western European ...
June 08, 2021 | News
Most Read
Bio Jobs
News
Editor Picks